A Stable Irinotecan Liposome with Enhanced Antitumor Activity in a Range of Tumor Models.

Abstract

This study aimed to prepare a stable irinotecan liposome(CPT-11 liposome) and evaluate its antitumor efficacy in a range of tumor models. CPT-11 liposome was prepared with a Z-average particle size of 110 ~ 120nm and high entrapment efficiency (> 95%) and had a good stability within 18months. Then the antitumor efficacy was studied in human colon (Ls-174t), gastric (NCI-N87), pancreatic (BxPC-3) and small cell lung (NCI-H526) cancer xenograft models. The toxicity of high-dose CPT-11 liposome was also evaluated in Beagle dogs. The results showed that the anti-tumor effects of CPT-11 liposome were markedly superior (at least 10 times higher) to those of the CPT-11 injection group in all four xenograft models. The tissue distribution test in the Ls-174t model further demonstrated that the CPT-11 liposome could alter the plasma and tissue distribution of CPT-11, increase the exposure level of its active metabolite SN-38 in tumor, and ultimately improve antitumor efficiency. Meanwhile, CPT-11 liposome showed a much less toxicity than CPT-11 injection in beagle dogs. Overall, the CPT-11 liposome may be developed as a new clinical alternative for the cancer patients.